Repatha (Evolocumab) 140 mg

Description

Effective Treatment for High Cholesterol and Cardiovascular Risk

Repatha (Evolocumab) is an advanced medication designed to significantly lower LDL cholesterol levels in patients with hyperlipidemia, particularly those at high risk for cardiovascular disease. It is primarily used as an adjunct to diet and statin therapy for patients with familial hypercholesterolemia or those who are unable to tolerate statins.

Unlike traditional cholesterol-lowering medications, Repatha works by inhibiting PCSK9, a protein that hinders the liver’s ability to remove LDL cholesterol. By blocking PCSK9, Repatha enhances the liver’s capacity to clear LDL-C from the bloodstream, dramatically reducing cholesterol levels and minimizing the risk of heart attacks and strokes.

Why Choose Repatha?

• Proven Efficacy: Demonstrates a substantial reduction in LDL-C levels, with proven clinical results in decreasing major cardiovascular events like heart attacks and strokes.

• No Statin Required: Ideal for those who cannot tolerate statins or need additional cholesterol-lowering therapy.

• Convenient Administration: Administered via a subcutaneous injection either bi-weekly or monthly, offering flexibility in treatment schedules.

• Proven Safety: Supported by extensive clinical data showing its safety and efficacy in lowering cholesterol.

Common Usage & Dosage

Repatha is typically administered as a subcutaneous injection once every two to four weeks, depending on the patient’s specific needs and healthcare provider’s recommendation. The dosage may vary based on the severity of hypercholesterolemia and the individual’s treatment plan.